Company / EPS (Diluted)
Candel Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.65
FY2023
5-year range
-$1.91 / -$0.65
FY2021-FY2023
Trend
+66.0%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-1.52 to $-0.65 over the past 2 years.
Based on SEC 10-K filings.
-0.65 in FY2023.
Improved from $-1.52 to $-0.65 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, eps (diluted) increased 66.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | -$0.65 | +66.0% |
| FY2022 | -$1.91 | -25.7% |
| FY2021 | -$1.52 | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026